Compare Advance Auto Parts, Inc. (AAP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Advance Auto Parts, Inc. trades at $53.07 (market cap $3.19B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Advance Auto Parts, Inc. pays a 1.89% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Advance Auto Parts, Inc. nearer its low. Which is the better fit depends on your goals.
| AAP | XBI | |
|---|---|---|
Market Cap | $3.19B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $64.17 | $164.28 |
52-Week Low | $38.75 | $86.92 |
Enterprise Value | $5.47B | — |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.52, down 3.97% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.77 versus $0.39 expected, but profitability remains thin with a net income margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain improvements, as noted in recent news (The Motley Fool, August 2026).
The outlook is cautious; while valuation appears reasonable with a P/S of 0.37 and analysts set a $61.30 consensus target, weak cash flow from operations and high debt pose risks. Investor sentiment is neutral amid restructuring efforts, but margin expansion and successful execution are critical for sustained recovery.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
